H
Hirotaka Nakayama
Researcher at Yokohama City University
Publications - 48
Citations - 1994
Hirotaka Nakayama is an academic researcher from Yokohama City University. The author has contributed to research in topics: Lenvatinib & Thyroid cancer. The author has an hindex of 15, co-authored 45 publications receiving 1586 citations.
Papers
More filters
Journal ArticleDOI
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer
Michael Mingzhao Xing,Ali S. Alzahrani,Kathryn A. Carson,David Viola,Rossella Elisei,Bela Bendlova,Linwah Yip,Caterina Mian,Federica Vianello,R. Michael Tuttle,Eyal Robenshtok,James A. Fagin,Efisio Puxeddu,Laura Fugazzola,Agnieszka Czarniecka,Barbara Jarzab,Christine J. O'Neill,Mark Sywak,Alfred King-Yin Lam,Garcilaso Riesco-Eizaguirre,Garcilaso Riesco-Eizaguirre,Pilar Santisteban,Hirotaka Nakayama,Ralph P. Tufano,Sara I. Pai,Martha A. Zeiger,William H. Westra,Douglas P. Clark,Roderick J. Clifton-Bligh,David Sidransky,Paul W. Ladenson,Vlasta Sykorova +31 more
TL;DR: In this retrospective multicenter study, the presence of the BRAF V600E mutation was significantly associated with increased cancer-related mortality among patients with PTC, and the association was not independent of tumor features.
Journal ArticleDOI
Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
Mingzhao Xing,Ali S. Alzahrani,Kathryn A. Carson,Young Kee Shong,Tae Yong Kim,David Viola,Rossella Elisei,Bela Bendlova,Linwah Yip,Caterina Mian,Federica Vianello,R. Michael Tuttle,Eyal Robenshtok,James A. Fagin,Efisio Puxeddu,Laura Fugazzola,Agnieszka Czarniecka,Barbara Jarzab,Christine J. O'Neill,Mark Sywak,Alfred King-Yin Lam,Garcilaso Riesco-Eizaguirre,Pilar Santisteban,Hirotaka Nakayama,Roderick J. Clifton-Bligh,Giovanni Tallini,Elizabeth H. Holt,Vlasta Sýkorová +27 more
TL;DR: BRAF mutation was associated with poorer recurrence-free probability in Kaplan-Meier survival analyses in various clinicopathologic categories and demonstrated an independent prognostic value of BRAF V600E mutation for PTC recurrence in various clinical categories.
Journal ArticleDOI
Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma
Iwao Sugitani,Yasuhiro Ito,Dai Takeuchi,Hirotaka Nakayama,Chie Masaki,Hisakazu Shindo,Masanori Teshima,Kazuhiko Horiguchi,Yusaku Yoshida,Toshiharu Kanai,Mitsuyoshi Hirokawa,Kiyomi Y Hames,Isao Tabei,Akira Miyauchi +13 more
TL;DR: If appropriately applied, AS of low-risk PTMC is a safe management strategy offering favorable outcomes and preserves quality of life at low cost.
Journal ArticleDOI
Prognostic value of the sixth edition AJCC/UICC TNM classification for differentiated thyroid carcinoma with extrathyroid extension.
Nobuyuki Wada,Hirotaka Nakayama,Nobuyasu Suganuma,Yoshihiko Masudo,Yasushi Rino,Munetaka Masuda,Toshio Imada +6 more
TL;DR: The sixth edition more accurately predicts different outcomes according to the revised criteria for the degree of extrathyroid extension, as well as Cox proportional hazard analysis.
Journal Article
Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
Hirotaka Nakayama,Akira Yoshida,Yoshiyasu Nakamura,Hiroyuki Hayashi,Youhei Miyagi,Nobuyuki Wada,Yasushi Rino,Munetaka Masuda,Toshio Imada +8 more
TL;DR: PTCs with BRAF (V600E) mutation are more aggressive than those with wildtype BRAF, and this mutation may be important for predicting a worse prognosis in patients with PTC.